MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says CannEpil+ to treat refractory epilepsy, has been approved for import into the UK by the Medicines & Healthcare products Regulatory Agency via its UK distribution and clinical access partner Elite Pharmaco. Further, it is the first time that an epilepsy treatment currently in a clinical trial process, and containing THC, has been approved by the authorities in the UK for import, MGC adds.
Co-founder and Managing Director Roby Zomer says: "The approval for the import of CannEpil+ to the UK and the associated compassionate prescriptions is an important step towards our global roll out of the treatment, and our continued commitment to patients. Achieving MHRA approval has been an ongoing process for some time with our UK partner Elite Pharmaco, and we expect the first patients in the UK to begin treat with CannEpil+ in the coming months."
Current stock price: 3.27 pence
Year-to-date change: up 37%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.